What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 6 months ago
VIDEO: No Glory in GLORIA
Dr. Richard Conway discusses abstract OP0263 presented at #EULAR2022.
https://t.co/tlsTPztYqY https://t.co/5dOma69vLZ
An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation. Studies of long-term outcomes and product formulation effects are lacking.
Dr. John Cush RheumNow
3 years 6 months ago
Baricitinib (JAK1/2 inhib) in 10 pts w/ systemic sclerosis showed improvement in modified Rodnan Skin Score ( −11.67 @wk 24; p=0.0008); 3/4 w/ digital ulcers healed at week 24. Similar findings seen in bleomycin induced animal model https://t.co/1G9CGjLK2N https://t.co/Gt35DcMyuz
Dr. John Cush RheumNow
3 years 6 months ago
Watch: Let’s Talk about Sex and Autoimmune Disease
Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022.
https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51
Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked. Two abstracts have shed light on relevant gender-based differences in AxSpA assessment or treatment.
TheDaoIndex KDAO2011
3 years 6 months ago
My new blog on “Emerging Therapeutics for #Lupus” #EULAR22 @RheumNow. Tagging @RichardPAConway because he doesn’t sleep. https://t.co/6a8Y00Aw4W
Dr. John Cush RheumNow
3 years 6 months ago
Watch: Demystifying Synovial Tissue Biology
Dr. Aurelie Najm ( @AurelieRheumo) discusses abstracts OP0084 and OP0085 presented at #EULAR2022.
https://t.co/LNfFmxiE8O https://t.co/aiLvdtxYRB
Dr. John Cush RheumNow
3 years 6 months ago
Malignancy risk on b/tsDMARDs in patients with prior malignancy history
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.
https://t.co/cZwJFoqx0C https://t.co/QgoN0Qd5yz
Dr. John Cush RheumNow
3 years 6 months ago
VIDEO: Golden Window in Pre-RA
Dr. Richard Conway ( @RichardPAConway) discusses abstract OP0070 presented at #EULAR2022.
https://t.co/VoVo4TTgvO https://t.co/7NrZqJlwjo
Dr. John Cush RheumNow
3 years 6 months ago
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/AVQ7lRYoRw
The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy.
Dr. John Cush RheumNow
3 years 6 months ago
PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals?
POS0309 at #EULAR2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies.
https://t.co/8newrxP1hn https://t.co/c9SwrRd8mw
Poster Hall